Protein quantification using Immuno-qPCR22nd May
Sensitive ligand-based protein quantification using immuno-PCR: A critical review of single-probe and proximity ligation assays
Image is © Olink AB
and used with permission
Life Science Sweden embraces ValidPrime™20th May
Life Science Sweden embraces ValidPrime™
- Offers a cost-efficient alternative to RT(-) controls
- Accurately validates qPCR assays in terms of their sensitivity to gDNA
- Allows correction for gDNA-derived signals
- Reduces the need for DNase treatment
Figure 1: Total number of RT and qPCR controls needed to check for gDNA background using traditional RT(-) approach and ValidPrime™. In an expression profiling experiment based on m samples and n assays, traditional set up requires m RT(-) reactions plus m x n qPCR controls, while using ValidPrime™ only m + n + 1 controls are needed.
“Is Laboratory Medicine ready to the era of personalized Medicine?”19th May
“Is Laboratory Medicine ready to the era of personalized Medicine?” The European Federation of Clinical Chemistry and Laboratory Medicine ask, and seeks your opinion:
Meet TATAA in Paris!15th May
Julia (top) and Maria (bottom) at our booth:
Ferentis awarded “Company of the Year”15th May
Ferentis awarded “Company of the Year” at European Lab Automation 2014
Prize delivered by Mikael Kubista, TATAA.
Ferentis is a new research-intensive biotechnology company involved in the development, production and commercialisation of peptides and biomimetic scaffolds for life-sciences and biomedical applications. The company is an exemplary new startup in life sciences – an entity encompassing translational, interdisciplinary and international co-operation. The company was started in Vilnius, Lithuania, by a group of 4 scientists and entrepreneurs from Canada, Lithuania, Sweden and India. It was born as a result of collaborative research of its founders in the development of “smart” biomaterials that can promote regeneration of tissue cells within the patient without any need of long-term immunosuppressive drugs. The group combines a unique combination of skills, state-of-the-art scientific research and experience in the fields of biomaterials’ enhanced cell regeneration, medicinal chemistry, peptidomimetics and surface nano-technology.
TATAA at EMBO workshop12th May
Join TATAA at EMBO workshop “Unravelling Biological Secrets by Single-Cell Expression Profiling” Sept 25-26 in Heidelberg
Recent studies have demonstrated that the top-down approach of studying a group of cells of the same type in order to infer what is happening in an individual cell is wrong. The differences among cells of the same population are often dramatic and so too can be the consequences arising from it. Recently, new technological advances make it possible to have high resolution genomic and transcriptomic investigations at the single-cell level. This has led to the implementation of single-cell methods across a plethora of research fields.
Nature embraces TATAA courses9th May
Nature embraces TATAA courses in career feature article:
microRNA webinar7th May
microRNA Webinar by TATAA partner Exiqon